These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 12065877)
1. PAI-1 promoter polymorphism modulates uPA-PAI complex accumulation by breast cancer cells. Alvarez-Millán JJ; Bocos C; Ferrín V; Lucas AR; Ruibal A; Schneider J Oncology; 2002; 62(3):286-90. PubMed ID: 12065877 [TBL] [Abstract][Full Text] [Related]
2. Association of uPA and PAI-1 tumor levels and 4G/5G variants of PAI-1 gene with disease outcome in luminal HER2-negative node-negative breast cancer patients treated with adjuvant endocrine therapy. Jevrić M; Matić IZ; Krivokuća A; Đorđić Crnogorac M; Besu I; Damjanović A; Branković-Magić M; Milovanović Z; Gavrilović D; Susnjar S; Kisić Tepavčević D; Stanojković T BMC Cancer; 2019 Jan; 19(1):71. PubMed ID: 30646864 [TBL] [Abstract][Full Text] [Related]
3. PAI-1 -675 4G/5G polymorphism as a prognostic biomarker in breast cancer. Lei H; Hemminki K; Johansson R; Altieri A; Enquist K; Henriksson R; Lenner P; Försti A Breast Cancer Res Treat; 2008 May; 109(1):165-75. PubMed ID: 17616807 [TBL] [Abstract][Full Text] [Related]
4. Markers of the uPA system and common prognostic factors in breast cancer. Minisini AM; Fabbro D; Di Loreto C; Pestrin M; Russo S; Cardellino GG; Andreetta C; Damante G; Puglisi F Am J Clin Pathol; 2007 Jul; 128(1):112-7. PubMed ID: 17580278 [TBL] [Abstract][Full Text] [Related]
5. Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity. Castelló R; España F; Vázquez C; Fuster C; Almenar SM; Aznar J; Estellés A Thromb Res; 2006; 117(5):487-92. PubMed ID: 15907980 [TBL] [Abstract][Full Text] [Related]
6. Plasminogen activator inhibitor-1 (PAI-1) gene 4G/5G promoter polymorphism is not associated with breast cancer. Błasiak J; Smolarz B Acta Biochim Pol; 2000; 47(1):191-9. PubMed ID: 10961693 [TBL] [Abstract][Full Text] [Related]
7. Plasminogen activator inhibitor -1 gene 4G/5G polymorphism in patients with breast cancer. Eroglu A; Ulu A; Cam R; Akar N J BUON; 2006; 11(4):481-4. PubMed ID: 17309181 [TBL] [Abstract][Full Text] [Related]
8. Plasminogen activator inhibitor 1 (PAI-1) levels and gene promoter polymorphisms in subjects with colorectal cancer. Smolarz B; Blasiak J; Kulig A; Romanowicz-Makowska H; Dziki A; Ulanska J; Pander B; Szewczyk T J Exp Clin Cancer Res; 2001 Jun; 20(2):247-52. PubMed ID: 11484982 [TBL] [Abstract][Full Text] [Related]
9. PAI-1 expression and its regulation by promoter 4G/5G polymorphism in clear cell renal cell carcinoma. Choi JW; Lee JH; Park HS; Kim YS J Clin Pathol; 2011 Oct; 64(10):893-7. PubMed ID: 21725041 [TBL] [Abstract][Full Text] [Related]
10. Clinicopathological significance of plasminogen activator inhibitor-1 promoter 4G/5G polymorphism in breast cancer: a meta-analysis. Lee JH; Kim Y; Choi JW; Kim YS Arch Med Res; 2013 Jan; 44(1):39-45. PubMed ID: 23291383 [TBL] [Abstract][Full Text] [Related]
11. Diabetic retinopathy, promoter (4G/5G) polymorphism of PAI-1 gene, and PAI-1 activity in Pima Indians with type 2 diabetes. Nagi DK; McCormack LJ; Mohamed-Ali V; Yudkin JS; Knowler WC; Grant PJ Diabetes Care; 1997 Aug; 20(8):1304-9. PubMed ID: 9250459 [TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphism of the plasminogen activator inhibitor-1 is associated with an increased risk of endometrial cancer. Su CK; Yeh KT; Yeh CB; Wang PH; Ho ES; Chou MC; Liu KC; Yang SF; Yi YC J Surg Oncol; 2011 Dec; 104(7):755-9. PubMed ID: 21761413 [TBL] [Abstract][Full Text] [Related]
13. Association of the plasminogen activator inhibitor-1 (PAI-1) Gene -675 4G/5G and -844 A/G promoter polymorphism with risk of keloid in a Chinese Han population. Wang Y; Long J; Wang X; Sun Y Med Sci Monit; 2014 Oct; 20():2069-73. PubMed ID: 25350781 [TBL] [Abstract][Full Text] [Related]
14. Relationship between gene polymorphism of the PAI-1 promoter and myocardial infarction. Fu L; Jin H; Song K; Zhang C; Shen J; Huang Y Chin Med J (Engl); 2001 Mar; 114(3):266-9. PubMed ID: 11780311 [TBL] [Abstract][Full Text] [Related]
15. Association of the 4G/5G polymorphism in the promoter region of plasminogen activator inhibitor-1 with abdominal aortic aneurysms. Rossaak JI; Van Rij AM; Jones GT; Harris EL J Vasc Surg; 2000 May; 31(5):1026-32. PubMed ID: 10805895 [TBL] [Abstract][Full Text] [Related]
16. 4G/5G polymorphism of PAI-1 gene promoter and fibrinolytic capacity in patients with deep vein thrombosis. Sartori MT; Wiman B; Vettore S; Dazzi F; Girolami A; Patrassi GM Thromb Haemost; 1998 Dec; 80(6):956-60. PubMed ID: 9869167 [TBL] [Abstract][Full Text] [Related]
17. [Plasminogen activator inhibitor-1 (PAI-1) 4G/5G and angiotensin converting enzyme (ACE) I/D gene polymorphisms and fibrinolytic activity in patients with essential hypertension and dyslipidemia]. Jastrzebska M; Widecka K; Ciechanowicz A; Goracy I; Wesołowska T; Torbus-Lisiecka B; Foltyńska-Nowakowska A; Naruszewicz M Pol Arch Med Wewn; 2005 Jan; 113(1):7-20. PubMed ID: 16130596 [TBL] [Abstract][Full Text] [Related]
18. Plasminogen activator inhibitor 1 expression in platelets is not influenced by the 4G/5G promoter polymorphism. Brogren H; Wallmark K; Jern S; Karlsson L Thromb Res; 2008; 121(6):793-7. PubMed ID: 17884148 [TBL] [Abstract][Full Text] [Related]
19. Association of PAI-1 4G/5G and -844G/A gene polymorphisms and changes in PAI-1/tissue plasminogen activator levels in myocardial infarction: a case-control study. Abboud N; Ghazouani L; Saidi S; Ben-Hadj-Khalifa S; Addad F; Almawi WY; Mahjoub T Genet Test Mol Biomarkers; 2010 Feb; 14(1):23-7. PubMed ID: 19929406 [TBL] [Abstract][Full Text] [Related]
20. The Association of Plasminogen Activator Inhibitor Type 1 (PAI-1) Level and PAI-1 4G/5G Gene Polymorphism with the Formation and the Grade of Endometrial Cancer. Yıldırım ME; Karakuş S; Kurtulgan HK; Kılıçgün H; Erşan S; Bakır S Biochem Genet; 2017 Aug; 55(4):314-321. PubMed ID: 28303356 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]